JCO Global Oncology最新文献

{"title":"Cost-Effectiveness of Lung Cancer Screening in a High-Risk Population in Brazil.","authors":"Clarissa Baldotto, Wolfgang W Schmidt Aguiar, Francisco Martins Neto, Vladmir Cordeiro de Lima, Eldsamira Mascarenhas, Thiago Lins Fagundes Sousa, Tamiê de Camargo Martins, Mauricio Cristiano Rocha-Junior, Cintia Kurokawa La Scala de Oliveira, Nelson Francisco Correa-Netto, Gustavo Faibischew Prado","doi":"10.1200/GO-25-00097","DOIUrl":"https://doi.org/10.1200/GO-25-00097","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to assess whether lung cancer (LC) screening with low-dose computed tomography (LDCT) is cost effective in a high-risk population (current or former smokers-who stopped smoking within <15 years-age 50-80 years, with a smoking history of at least 20 pack-years) in the Brazilian public health setting.</p><p><strong>Methods: </strong>To estimate the size of the population eligible for screening, we used Brazilian 2020 census data and information provided by the nationwide surveillance system of risk factors for chronic diseases. For comparison, we used a nonscreened population of LC cases from the São Paulo state registry. We characterized patient journeys and estimated direct and indirect costs using the nationwide public health system database, DATASUS, and expert opinion from an ad hoc panel. We used Markov models for economic evaluations that considered treatment costs (in Brazilian currency, R$) and outcomes.</p><p><strong>Results: </strong>Adopting an LC screening strategy with LDCT in this high-risk population would be associated with an incremental cost-effectiveness ratio (ICER) of R$ 133,327 per quality-adjusted life year. For the life year outcome, the ICER was R$ 9,579 per life year gained. For both outcomes, the values were below the cost-effectiveness threshold considered (three times the per-capita gross domestic product, which corresponds to R$ 143,406.06 or $24,735.99 US dollars).</p><p><strong>Conclusion: </strong>Our study confirms that implementing LC screening with LDCT in a high-risk population is cost effective in the Brazilian public health system.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500097"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing Requirements for Breast Centers in Low- and Middle-Income Countries: A South African Perspective.","authors":"Sarah Nietz, Jenny Edge, Ines Buccimazza, Georgia Demetriou, Mariza Tunmer, Jacqueline Smilg, Duvern Ramiah, Peter Schoub, Shane A Norris, Paul Ruff","doi":"10.1200/GO-25-00168","DOIUrl":"https://doi.org/10.1200/GO-25-00168","url":null,"abstract":"<p><strong>Purpose: </strong>In South Africa, breast care lacks governance and standardization, necessitating urgent improvements in patient outcomes. Quality improvement initiatives are urgently needed in low- and middle-income countries (LMICs), but requirements for breast centers in lower resource settings remain undefined and must be tailored to local environments. This consensus document outlines the role and requirements of breast centers in LMICs and presents a step-by-step implementation plan.</p><p><strong>Methods: </strong>The literature was systematically reviewed, and the primary review team tabulated international accreditation standards alongside the 2018 South African Clinical Guidelines for Breast Cancer Control and Management from the South African National Department of Health, along with proposed South African standards. The broader consensus panel consisted of 29 clinical experts and representatives from societies, advocacy, and funders.</p><p><strong>Results: </strong>We categorized requirements into eight broader categories and achieved unanimous consensus on all requirement components, except for 1 abstention in the general specialist and expertise category. We were unable to reach consensus on the patient volume requirements for radiologists as well as for medical and clinical/radiation oncologists. Volume requirements for clinical and radiation oncologists were later provided by the South African Society of Clinical and Radiation Oncology (SASCRO), along with the volume requirements submitted by the participating radiologists. We also achieved unanimous consensus for the Breast Interest Group of Southern Africa (BIGOSA) to house the initial project implementation. This consensus document is endorsed by BIGOSA, SASCRO, and the Cancer Association of South Africa.</p><p><strong>Conclusion: </strong>We emphasize the importance and necessity of breast centers in resource-constrained environments, outline the first set of requirements for breast centers tailored to LMICs in sub-Saharan Africa, and present a feasible and detailed plan for initial implementation.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500168"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Outcomes of Adolescent and Young Adult Women With Breast Cancer in Rural and Urban Saskatchewan: A Retrospective Cohort Study.","authors":"Erika Arnold, Devin Laubscher, Huzaifa Saeed, Osama Ahmed, Ayesha Bashir, Haji Chalchal, Gary Groot, Duc Le, Mita Manna, Pamela Meiers, Prosanta Mondal, Shahid Ahmed","doi":"10.1200/GO-25-00277","DOIUrl":"10.1200/GO-25-00277","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500277"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144289445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Mineral Density in Black South African Women Newly Diagnosed With Breast Cancer Living With and Without HIV.","authors":"Lindor Qunaj, Maureen Joffe, Alfred I Neugut, Lisa K Micklesfield","doi":"10.1200/GO-25-00122","DOIUrl":"10.1200/GO-25-00122","url":null,"abstract":"<p><strong>Purpose: </strong>Worsening bone mineral density (BMD)-and the corresponding increase in osteoporotic fractures-is an important and well-established source of morbidity and mortality in women receiving treatment of breast cancer, as well as those living with HIV. However, there are comparatively few reports on pretreatment bone health in women newly diagnosed with breast cancer, especially in predominantly Black populations, across sub-Saharan Africa (SSA), and among individuals living with HIV. Therefore, we sought to characterize bone health in a cohort of Black South African women with and without HIV before the initiation of systemic breast cancer therapy, in particular chemotherapy and/or aromatase inhibitors.</p><p><strong>Methods: </strong>Building on the South African Breast Cancer and HIV Outcomes study, we recruited consecutive women newly diagnosed with stage I-III breast cancer who were to start systemic cancer therapy at the Chris Hani Baragwanath Academic Hospital in Soweto, Johannesburg, between June 2021 and August 2024. In addition to collecting extensive demographic and clinical information, we conducted dual energy X-ray absorptiometry (DXA) scans on each patient to measure BMD of the lumbar spine, femoral neck, and total hip.</p><p><strong>Results: </strong>We enrolled a total of 378 women, 32.3% of whom (n = 122) were living with HIV. Among women aged 50 years and older (n = 156), 64.1% had osteopenia or osteoporosis; HIV infection and vitamin D insufficiency/deficiency-but no breast cancer characteristics-were associated with a higher risk of osteoporosis. By contrast, 3.6% of women younger than 50 years had BMD below the expected range for age.</p><p><strong>Conclusion: </strong>Especially in low-resource clinical settings, such as public hospitals in SSA, understanding which women are at highest risk of osteoporosis and fragility fracture before the initiation of breast cancer systemic therapy is critical. Our study provides a foundation for identifying relevant risk factors and ultimately designing interventional studies that target high-risk women for intensified osteoporosis screening and management.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500122"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pragmatic Approach to Hepatocellular Carcinoma Diagnosis in High-Incidence, Resource-Limited Settings in Africa.","authors":"Gregory D Kirk, Sara Nsibirwa, Jim K Aizire, Redeat L Assefa, Antonio Bandala-Jacques, Jackson Orem, Tongai Maponga, Moussa Seydi, Gilles Wandeler, Amir Mohareb, David L Thomas, Fred Okuku, Emmanuelle Ochola, Ponsiano Ocama","doi":"10.1200/GO-24-00592","DOIUrl":"10.1200/GO-24-00592","url":null,"abstract":"<p><strong>Purpose: </strong>Hepatocellular carcinoma (HCC) is common and deadly in sub-Saharan Africa, where advanced imaging techniques, such as computerized tomography and magnetic resonance imaging, are scarce. The purpose of this study was to develop a pragmatic HCC diagnostic strategy for such settings.</p><p><strong>Methods: </strong>We evaluated standardized protocol-collected data on clinical, ultrasonographic, biochemical, and pathological criteria in a multisite study of 649 suspected HCC cases in Uganda. Participants underwent standardized interviews, clinical assessments, and ultrasound examinations by trained staff with alpha-fetoprotein (AFP) testing at a central laboratory, and pathology was obtained for selected participants. Concordance analysis and percentage-confirmed yield using different HCC case definitions were performed, with survival follow-up as a validation measure.</p><p><strong>Results: </strong>The median age was 45 years, 68% were male, and 45% had chronic hepatitis B infection. Ultrasonographic, biochemical (AFP), and pathological definitions confirmed 91%, 57%, and 17% of clinically defined HCC cases, respectively. The median survival after diagnosis was 46 days. An integrated HCC case definition that combined clinical criteria with one confirmatory test increased the percentage-confirmed yield by 3.7% (ultrasonographic), 37.7% (biochemical), and 77.7% (pathologic) over the clinical definition alone. Yield from AFP or pathology beyond ultrasound was minimal. Survival did not differ appreciably by HCC case definition. This integrated HCC case definition maintained diagnostic rigor while maximizing yield.</p><p><strong>Conclusion: </strong>We propose an integrated HCC case definition as a pragmatic, resource-adaptable approach for clinical diagnosis and research in sub-Saharan Africa. This definition can be readily implemented and can support regional collaborative efforts to develop novel diagnostics and improved treatments to ameliorate the heavy HCC burden.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400592"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"I Wait for Leftover Morphine: A Qualitative Study of Barriers to Safe Opioid Access for Cancer Pain Relief in Vietnam.","authors":"Trang Nguyen, Anh Dam, Linh Bui, Tung Pham, Eric L Krakauer, Caroline Phelan","doi":"10.1200/GO-25-00026","DOIUrl":"https://doi.org/10.1200/GO-25-00026","url":null,"abstract":"<p><strong>Purpose: </strong>This study explores the views of health care providers (HCPs), regulators, patients with cancer, and caregivers in Vietnam on the barriers to safe access to opioids for cancer pain relief and suggested solutions.</p><p><strong>Materials and methods: </strong>We conducted a qualitative, descriptive study using semistructured interviews. Five HCPs, six patients with cancer/caregivers, and six regulators (n = 17) were purposefully sampled across Vietnam. Audio recordings were transcribed verbatim and subjected to inductive content analysis using a Framework method.</p><p><strong>Results: </strong>Five categories of barriers were identified: (1) Patient-related barriers (fear of addiction and other side effects, morphine's association with impending death); (2) professional-related barriers (knowledge and experience deficit, fear of addiction and other side effects, and concerns about diversion and liabilities); (3) medicine-related barriers (limited oral morphine availability, limited manufacturers and suppliers, and difficulties accessing parenteral opioids); (4) regulatory barriers (difficulties obtaining certifications of continued need for opioid use, overly strict regulation enforcement, lack of information on opioid distribution channels); and (5) services delivery barriers (scarce palliative and home care services). Potential solutions include strengthening education for patients, communities, and health care professionals; mandating oral morphine availability at district levels; diversifying opioid variety and enhancing domestic manufacturing; establishing an electronic prescription monitoring system; expanding palliative care training and implementation across all health care system levels; and using telemedicine.</p><p><strong>Conclusion: </strong>Barriers to opioid access for cancer pain control in Vietnam are multifactorial and interrelated, necessitating interdisciplinary solutions.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500026"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Distress and Effectiveness of Survivor Video Narratives on Cancer-Associated Distress in Botswana: A Pilot Study.","authors":"Yehoda M Martei, Maanasa Gurram, Lebogang T Mokokwe, Ngwao Ngwako, Keaobaka Kebuang, Dipho I Setlhako, Peter Vuylsteke, Baaitse Bontswanetse, Tumisang Segadimo, Mosepele Mosepele, Lawrence N Shulman, Frances Barg, Babe E Gaolebale","doi":"10.1200/GO-24-00474","DOIUrl":"10.1200/GO-24-00474","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate baseline distress among patients with breast cancer in Botswana, and assess the impact of culturally tailored peer survivor video narratives on distress and its mediators.</p><p><strong>Methods: </strong>We enrolled patients with stage I-IV breast cancer at Princess Marina Hospital. A Setswana-translated National Comprehensive Cancer Network distress thermometer (DT) and problem list (PL) were used for distress screening. DT score of ≥4 was considered a positive screen for moderate to high (moderate-high) distress. We analyzed independent PL factors associated with moderate-high distress using logistic regression. Participants then watched one to two videos and completed a postintervention DT/PL assessment after each video at 4 and 8 weeks. We conducted descriptive statistics to explore the impact of the videos.</p><p><strong>Results: </strong>One hundred six participants were enrolled, of whom 103 completed baseline DT and 106 completed baseline PL. Sixty-seven percent (69/103) of participants screened positive for moderate-high distress at baseline. Fear (odds ratio [OR], 11.25 [95% CI, 1.66 to 76.49]; <i>P</i> = .01) and appearance (OR, 4.96 [95% CI, 1.03 to 23.80]; <i>P</i> = .046) were PL factors significantly associated with moderate-high distress in the multivariable model. Sixty-eight and 47 participants completed postvideo assessments at approximately 4 and approximately 8 weeks, respectively. The greatest impact was observed at 8 weeks after watching two videos-29.8% of participants with moderate-high distress had no or mild distress. Similarly, there was a 29% (44%-15%; <i>P</i> = .005) and 17% (32%-15%; <i>P</i> = .03) absolute decrease from baseline to 8 weeks, in the proportion of patients who identified fear and appearance as sources of distress, respectively.</p><p><strong>Conclusion: </strong>Two thirds of patients with breast cancer screened positive for moderate-high distress. Fear and appearance were sources of distress significantly associated with a positive screen. Our results show promising potential of peer survivor videos to mitigate distress and its potential mediators among patients with breast cancer.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400474"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Genetic Ancestry and Colorectal Cancer Risk in a Large Brazilian Cohort: Replication of Single-Nucleotide Polymorphisms Identified by Genome-Wide Association Studies.","authors":"Ana Carolina de Carvalho, Ana Carolina Laus, Howard Ribeiro Lopes Junior, Jun Porto, Débora Sant'Anna Silva, Adeylson Guimarães Ribeiro, José Guilherme Datorre, Rosielly Melo Tavares, Anne Beatriz Sousa Carlos, Tulio Furquim, Miyuki Uno, Roger Chammas, Priscilla Villela, Mariana Bisarro Dos Reis, Marcus de Medeiros Matsushita, Marco Antônio Oliveira, Welinton Yoshio Hirai, Denise Peixoto Guimarães, Florinda Almeida Santos, Rui Manuel Reis","doi":"10.1200/GO-24-00512","DOIUrl":"https://doi.org/10.1200/GO-24-00512","url":null,"abstract":"<p><strong>Purpose: </strong>Genome-wide association studies have identified several single-nucleotide polymorphisms (SNPs) linked to colorectal cancer (CRC) risk in European and Asian populations, but studies in admixed populations, like Brazilians, remain scarce. We aimed to replicate 45 SNPs associated with CRC risk and explore their correlation with genetic ancestry in a large Brazilian cohort.</p><p><strong>Methods: </strong>A case-control study included 990 CRC cases and 1,027 controls in Brazil. We genotyped 45 SNPs using SNPtype assays and assessed ancestry with 46 ancestry informative markers. After matching cases and controls by sex and age, 906 cases and 906 controls were analyzed.</p><p><strong>Results: </strong>Genotyping succeeded for 35 SNPs, and nine showed significant CRC associations. Multivariate analysis confirmed two SNPs linked to increased CRC risk, rs10795668 (odds ratio [OR], 1.98; <i>P</i> = .003) and rs6066825 (OR, 1.50; <i>P</i> = .008), and two SNPs with protective effects: rs4939827 (OR, 0.61; <i>P</i> = .001) and rs6983267 (OR, 0.65; <i>P</i> = .013). Low Asian (lowest tercile, OR, 1.48; <i>P</i> = .001) and low African (lowest tercile, OR, 1.22; <i>P</i> = .025) ancestry increased CRC risk.</p><p><strong>Conclusion: </strong>Our findings validated rs10795668 (<i>LOC10537640</i>), rs4939827 (<i>SMAD7</i>), rs6066825 (<i>PREX1</i>), and rs6983267 (<i>CCAT2</i>) polymorphisms in CRC risk among Brazilians and suggest that lower Asian and African ancestries might influence CRC susceptibility.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400512"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Access to Multiple Myeloma Therapies.","authors":"Rawan Atallah, Yara Shatnawi, Md Fathima Shehnaz Ayoobkhan, Md Saiful Islam Saif, Menahil Naeem, Emerson Logan, Muhammad Umair Mushtaq, Shabeeha Rana, Aytaj Mammadzadeh, Shahrukh K Hashmi, Benlazar Mohamed, Nihar Desai, Thiago Xavier Carneiro, Rakesh Popat, Joseph P McGuirk, Shebli Atrash, Zahra Mahmoudjafari, Nada Hammad, Faiz Anwer, Nausheen Ahmed, Al-Ola Abdallah","doi":"10.1200/GO-24-00441","DOIUrl":"https://doi.org/10.1200/GO-24-00441","url":null,"abstract":"<p><strong>Purpose: </strong>Initial reports indicate that access to contemporary therapies currently used in North America for the treatment of multiple myeloma (MM) varies internationally. No studies have quantitatively reported the extent of disparities in the access to MM therapies worldwide, with a goal to investigate access to MM therapies and barriers globally.</p><p><strong>Methods: </strong>From June 18 to July 15, 2023, an electronic survey was distributed to 176 oncologists treating MM outside the United States. MM drugs were categorized by accessibility, with the cutoff for adequate access set at 60% of respondents affirming easy/moderate access.</p><p><strong>Results: </strong>Ninety-five (54%) respondents from 33 countries completed the survey. Fifty-one percent of the respondents were from university-based academic programs, and 17% of the responders treated only plasma cell disorders. Most respondents had adequate access to noncellular MM therapies, except for isatuximab, ixazomib, selinexor, and elotuzumab. Among the cellular therapies, 17% had access to Chimeric Antigen Receptor T-cell therapy, whereas 23% had access to approved T-cell engagers (TCEs). Financial stress on patients and health care systems has emerged as a primary barrier to global inaccessibility of treatment drugs.</p><p><strong>Conclusion: </strong>Global access to novel MM therapies remains challenging, and we have identified barriers and suggested strategies to bridge this gap.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400441"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Armed Conflict on Cancer Care in Sudan: Challenges and Strategic Responses.","authors":"Yasar Ahmed, Nabeeha Karadawi, Mutasim Abubaker, Awad Mustafa","doi":"10.1200/GO-24-00568","DOIUrl":"https://doi.org/10.1200/GO-24-00568","url":null,"abstract":"<p><p>The armed conflict that erupted in Sudan on April 15, 2023, has precipitated a catastrophic collapse of the nation's health care system, with oncology services bearing particularly devastating consequences. Once a regional leader in cancer care, Sudan's health care infrastructure, including its flagship Khartoum Oncology Hospital and numerous comprehensive cancer centers, has been rendered nearly nonfunctional. This crisis has left thousands of patients with cancer without access to essential treatments, exacerbating an already dire public health situation. The conflict has not only disrupted medical supply chains but also displaced health care personnel, further crippling the ability to deliver life-saving care. This manuscript provides a critical analysis of the impact of the conflict on cancer care in Sudan, focusing on the redistribution of patients to peripheral oncology centers and the strain on these facilities. Although existing literature has highlighted the collapse of health care infrastructure, this study offers new quantitative data on the surge in patient numbers at centers such as the East Oncology Centre and the White Nile Cancer Centre, alongside the critical shortages of medical supplies. It also underscores the equity concerns arising from the lack of global attention to Sudan's cancer care crisis compared with other conflict zones. By shedding light on these issues, this study aims to galvanize international action to support Sudanese patients with cancer and rebuild its health care system.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400568"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}